Skip to main content

Table 1 Identified putative markers in lung cancers using the in silico reverse transcriptomics approach.

From: A novel in silicoreverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer

Group

LC Types

Gene sets

1

Unique to SCLC

RB1, E2F1, E2F2, CCNT2, CMYC, CEBPA, TP53, CDKN2A, HDAC4

2

Common to SCLC and NSCLC

RB1, E2F1, E2F2, CCNT2, CMYC, CEBPA, TP53, CDKN2A, HDAC4

3

Common to general, SCLC, and NSCLC

RB1, E2F1, E2F2, CCNT2, CMYC, CEBPA, TP53, CDKN2A, HDAC4

4

Common to NSCLC and general

TFDP2, AHR, CCND1, TP73, RBL2, TAF1, PML, BCL6, MYB, WT1, PARP1, PCAF, TWIST, MCM7

5

NSCLC specific

E2F6, TFDP1, SUV39H1, HNRPD

6

General/ common path specific

RBL1, IRF1, HMGA1

  1. The markers can be used in combination to design panels for diagnosis of sub-type specific lung cancers.